002020 京新药业
已收盘 02-04 15:00:00
资讯
新帖
简况
京新药业：公司的重酒石酸卡巴拉汀目前销售额较小
证券之星 · 01-30
京新药业：公司的重酒石酸卡巴拉汀目前销售额较小
京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验
证券之星 · 01-30
京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验
京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配
证券之星 · 01-30
京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配
京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%
证券之星 · 01-28
京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%
股市必读：京新药业（002020）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：京新药业（002020）1月23日董秘有最新回复
京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中
证券之星 · 01-25
京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中
京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%
证券之星 · 01-22
京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%
京新药业：AI在研发的应用还处在持续摸索阶段
证券之星 · 01-16
京新药业：AI在研发的应用还处在持续摸索阶段
京新药业(002020.SZ)筹划赴港上市事项
智通财经 · 01-13
京新药业(002020.SZ)筹划赴港上市事项
1月12日京新药业（002020）龙虎榜数据：游资呼家楼上榜
证券之星 · 01-12
1月12日京新药业（002020）龙虎榜数据：游资呼家楼上榜
1月12日京新药业跌6.00%，招商景气优选股票A基金重仓该股
证券之星 · 01-12
1月12日京新药业跌6.00%，招商景气优选股票A基金重仓该股
京新药业：深圳巨烽坚持研发投入助力国产替代
证券之星 · 01-12
京新药业：深圳巨烽坚持研发投入助力国产替代
京新药业（002020）披露回购公司股份期限届满暨回购实施完成公告，1月7日股价上涨1.89%
证券之星 · 01-07
京新药业（002020）披露回购公司股份期限届满暨回购实施完成公告，1月7日股价上涨1.89%
京新药业（002020）披露股份回购进展公告，1月5日股价上涨3.16%
证券之星 · 01-05
京新药业（002020）披露股份回购进展公告，1月5日股价上涨3.16%
股市必读：京新药业（002020）12月30日董秘有最新回复
证券之星 · 2025-12-31
股市必读：京新药业（002020）12月30日董秘有最新回复
股市必读：京新药业（002020）12月29日董秘有最新回复
证券之星 · 2025-12-30
股市必读：京新药业（002020）12月29日董秘有最新回复
京新药业：LP（a）降脂创新药临床I期接近尾声
证券之星 · 2025-12-29
京新药业：LP（a）降脂创新药临床I期接近尾声
京新药业：LP（a）机制降脂新药对外授权进展中
证券之星 · 2025-12-11
京新药业：LP（a）机制降脂新药对外授权进展中
京新药业：在精神分裂细分适应症上做差异化布局
证券之星 · 2025-12-11
京新药业：在精神分裂细分适应症上做差异化布局
京新药业：地达西尼销售正常推进中
证券之星 · 2025-12-07
京新药业：地达西尼销售正常推进中
加载更多
公司概况
公司名称：
浙江京新药业股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-15
主营业务：
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格：
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":16.8,"timestamp":1770188625000,"preClose":16.64,"halted":0,"volume":7094580,"delay":0,"changeRate":0.0096,"floatShares":724000000,"shares":861000000,"eps":0.8276,"marketStatus":"已收盘","change":0.16,"latestTime":"02-04 15:00:00","open":16.59,"high":16.82,"low":16.5,"amount":118000000,"amplitude":0.0192,"askPrice":16.8,"askSize":155,"bidPrice":16.79,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.8276,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.64,"symbolType":"stock","openAndCloseTimeList":[[1770168600000,1770175800000],[1770181200000,1770188400000]],"highLimit":18.3,"lowLimit":14.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.54,"roa":"--","peRate":20.299662,"roe":"10.1%","epsLYR":0.83,"committee":-0.450415,"marketValue":14465000000,"turnoverRate":0.0098,"status":0,"floatMarketCap":12163000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2607804591","title":"京新药业：公司的重酒石酸卡巴拉汀目前销售额较小","url":"https://stock-news.laohu8.com/highlight/detail?id=2607804591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607804591?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779452,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：印度产的重酒石酸卡巴拉汀胶囊被禁对公司而言是个好机会，目前公司国内份额多少？一年销售额多少？未来公司抓住机会可以扩大份额有信心吗？京新药业回复：您好!公司的重酒石酸卡巴拉汀目前销售额较小，公司希望后续可以通过集采机会获得好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2607459450","title":"京新药业：现有销售团队对于精神神经领域的药品销售有一定的经验","url":"https://stock-news.laohu8.com/highlight/detail?id=2607459450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607459450?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779452,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司申请上市的盐酸卡利拉嗪胶囊上市评审结束了，最快什么时候可以销售？公司做好生产上市准备了吗？预计国内市场规模大约多少？京新药业回复：您好！公司现有销售团队对于精神神经领域的药品销售有一定的经验，预期可以有效承接盐酸卡利拉嗪的商业化工作，争取取得好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2607045912","title":"京新药业：公司启动H股上市计划主要为与公司创新转型战略相匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2607045912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607045912?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:24","pubTimestamp":1769779444,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月30日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，A股上市企业去港股再上市，规定市值超400亿港币，或近一年利润不低于10亿港币，公司申请港股上市，目前符合那条，应该说利润9亿人民币更好达到吧！京新药业回复：您好！公司会按照监管规则推进H股上市事项，公司启动H股上市计划主要为与公司创新转型战略相匹配，坚持研发投入，做好创新布局，建立公司第二增长曲线。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000045258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2606712224","title":"京新药业（002020）披露2026年第一次临时股东会决议公告，1月28日股价下跌2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712224","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606712224?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:09","pubTimestamp":1769609359,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，京新药业报收于16.94元，较前一交易日下跌2.92%，最新总市值为145.86亿元。该股当日开盘17.46元，最高17.49元，最低16.83元，成交额达4.23亿元，换手率为3.43%。近日，京新药业发布《2026年第一次临时股东会决议公告》。表决结果均达到法定通过比例，会议召集程序合法合规。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2606539265","title":"股市必读：京新药业（002020）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606539265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606539265?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:05","pubTimestamp":1769367912,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，京新药业报收于18.05元，上涨0.11%，换手率1.44%，成交量10.42万手，成交额1.88亿元。公司公告汇总第四期员工持股计划首次授予部分非交易过户完成公告浙江京新药业股份有限公司已完成第四期员工持股计划首次授予部分的非交易过户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2606525088","title":"京新药业：公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2606525088","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606525088?lang=zh_cn&edition=full","pubTime":"2026-01-25 22:12","pubTimestamp":1769350337,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月25日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，大盘近几个月如此给力，公司却如此狼狈，而且公司回复问题还遮遮掩掩，毫无正能量，公司的BD业务以及盐酸卡利拉嗪进度什么情况？一切正常吗？为什么公司从不正面回复京新药业回复：您好！谢谢您对公司的关注，公司LP（a）的对外授权和盐酸卡利拉嗪都在正常推进中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500009303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2605922144","title":"京新药业（002020）披露第四期员工持股计划首次授予部分非交易过户完成，1月22日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605922144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605922144?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:15","pubTimestamp":1769091320,"startTime":"0","endTime":"0","summary":"近日，浙江京新药业股份有限公司披露第四期员工持股计划首次授予部分非交易过户完成公告。公司已完成第四期员工持股计划首次授予部分的非交易过户，公司回购专用账户中的712.34万股A股股票已于2026年1月21日通过非交易过户方式过户至员工持股计划专用账户，占公司总股本的0.83%，过户价格为12.50元/股。员工持股计划存续期为60个月，股票分三期解锁，解锁比例分别为40%、30%、30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2603995447","title":"京新药业：AI在研发的应用还处在持续摸索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603995447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603995447?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:52","pubTimestamp":1768567922,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在AI制药方面有应用？京新药业回复：您好！公司目前AI在研发的应用，还处在持续摸索阶段。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600038751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2603521415","title":"京新药业(002020.SZ)筹划赴港上市事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2603521415","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603521415?lang=zh_cn&edition=full","pubTime":"2026-01-13 06:31","pubTimestamp":1768257104,"startTime":"0","endTime":"0","summary":"智通财经APP讯，京新药业(002020.SZ)公告，公司拟发行境外上市股份(H股)并申请在中国香港联交所主板挂牌上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2602513366","title":"1月12日京新药业（002020）龙虎榜数据：游资呼家楼上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2602513366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602513366?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:45","pubTimestamp":1768211149,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月12日公布的交易公开信息显示，京新药业因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月12日收盘，京新药业报收于19.1元，下跌6.0%，换手率5.58%，成交量40.4万手，成交额7.7亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出5476.56万元，北向资金合计净卖出3365.48万元。呼家楼等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200024892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2602591077","title":"1月12日京新药业跌6.00%，招商景气优选股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602591077","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602591077?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:42","pubTimestamp":1768203732,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日京新药业跌6.00%，收盘报19.1元，换手率5.58%，成交量40.4万手，成交额7.7亿元。重仓京新药业的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为23.54。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为招商基金的招商景气优选股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2602598918","title":"京新药业：深圳巨烽坚持研发投入助力国产替代","url":"https://stock-news.laohu8.com/highlight/detail?id=2602598918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602598918?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:51","pubTimestamp":1768193467,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司深圳巨烽子公司做为全国最大医用显示器公司在人类技术方面有什么储备吗？未来在医用方面有考虑协足其领域吗？京新药业回复：您好！深圳巨烽主要提供医用显示模块解决方案，公司一直坚持研发投入，也希望可以与下游客户的先进医疗器械进行配套，助力国产替代。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200013051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2601809100","title":"京新药业（002020）披露回购公司股份期限届满暨回购实施完成公告，1月7日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601809100","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601809100?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:18","pubTimestamp":1767795498,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，京新药业报收于19.93元，较前一交易日上涨1.89%，最新总市值为171.6亿元。公司近日发布公告称，浙江京新药业股份有限公司于2025年1月8日召开董事会审议通过股份回购方案，拟用于股权激励或员工持股计划。截至2026年1月8日，公司累计回购股份4,727.1295万股，占总股本的5.49%，成交总金额60,872.22万元，回购期限届满，回购实施完成。回购期间相关主体无买卖公司股票行为，回购符合方案及相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2601008780","title":"京新药业（002020）披露股份回购进展公告，1月5日股价上涨3.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601008780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601008780?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:11","pubTimestamp":1767607862,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，京新药业报收于19.58元，较前一交易日上涨3.16%，最新总市值为168.59亿元。该股当日开盘18.98元，最高19.95元，最低18.91元，成交额达2.71亿元，换手率为1.91%。公司近日发布《关于股份回购进展公告》，称浙江京新药业股份有限公司于2025年1月8日审议通过股份回购方案，拟用于股权激励或员工持股计划，回购金额不低于3.5亿元且不超过7.0亿元，回购价格不超过14.47元/股。回购符合相关法规及既定方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2595671225","title":"股市必读：京新药业（002020）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595671225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595671225?lang=zh_cn&edition=full","pubTime":"2025-12-31 04:21","pubTimestamp":1767126070,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，京新药业报收于18.9元，下跌1.87%，换手率1.34%，成交量9.69万手，成交额1.84亿元。董秘最新回复投资者： 问公司吕董，公司降脂新药一期结束了吗？二期大约什么时间开始。做为新晋创新药公司，难道公司就没有机构调研吗？公司的LP降脂创新药临床I期接近尾声。公司会积极跟投资者交流，正确传达公司的经营进展。当日关注点来自交易信息汇总：12月30日主力资金净流出325.86万元，散户资金净流入511.02万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100004513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2595732519","title":"股市必读：京新药业（002020）12月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595732519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595732519?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:51","pubTimestamp":1767030670,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，京新药业报收于19.26元，下跌2.87%，换手率1.37%，成交量9.94万手，成交额1.93亿元。董秘最新回复投资者： 京新药业的 JX2201 目前处于 I期临床末尾，临床指标是不是达到预期效果，目前公司有没有准备启动2期临床的计划。公司的LP降脂创新药临床I期接近尾声，盐酸卡利拉嗪胶囊已提交上市申请，正常推进中，具体情况敬请关注定期报告。当日关注点来自交易信息汇总：12月29日主力资金净流出1452.2万元，显示主力资金呈离场态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000001073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2595789267","title":"京新药业：LP（a）降脂创新药临床I期接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789267","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789267?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:09","pubTimestamp":1767002953,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：京新药业的 JX2201 目前处于 I期临床末尾，临床指标是不是达到预期效果，目前公司有没有准备启动2期临床的计划。同时请问公司这款创新药在国内同行业中属于第几梯队在国际上属于什么层次？公司的LP降脂创新药临床I期接近尾声，盐酸卡利拉嗪胶囊已提交上市申请，正常推进中，具体情况敬请关注定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900025460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","002020","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2590592531","title":"京新药业：LP（a）机制降脂新药对外授权进展中","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590592531?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448474,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司降脂药创新药目前BD谈判到底进展如何？京新药业回复：您好！LP（a）机制降脂新药的对外授权工作进展中，公司会努力推进，若有进展敬请关注相关公告。谢谢!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2590592537","title":"京新药业：在精神分裂细分适应症上做差异化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590592537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590592537?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448473,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：公司回复说JX11502和盐酸卡利拉嗪都是针对精神分裂适应症，如果没有那为什么要重复研发多花钱做临床试验呢？京新药业回复：您好！公司会在精神分裂细分适应症上做差异化布局。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2589532873","title":"京新药业：地达西尼销售正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2589532873","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589532873?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:51","pubTimestamp":1765079468,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)12月07日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司新药地达西尼进入四季度后销售增速还象三季度吗？降脂新药CBD业务进展如何？京新药业回复：您好!公司治疗失眠的1类新药地达西尼目前销售正常推进中，公司会做好入院工作，争取实现更好的销售业绩。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700001370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770227353485,"stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.142},{"period":"3month","weight":-0.0744},{"period":"6month","weight":-0.1213},{"period":"1year","weight":0.4079},{"period":"ytd","weight":-0.1149}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"159962人(较上一季度增加616.74%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}